Context Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CNTX and other ETFs, options, and stocks.About CNTX
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers.
CEOMartin A. Lehr
CEOMartin A. Lehr
Employees12
Employees12
HeadquartersPhiladelphia, Pennsylvania
HeadquartersPhiladelphia, Pennsylvania
Founded2015
Founded2015
Employees12
Employees12
CNTX Key Statistics
Market cap106.12M
Market cap106.12M
Price-Earnings ratio-4.11
Price-Earnings ratio-4.11
Dividend yield—
Dividend yield—
Average volume813.25K
Average volume813.25K
High today$1.28
High today$1.28
Low today$1.11
Low today$1.11
Open price$1.12
Open price$1.12
Volume2.39M
Volume2.39M
52 Week high$1.55
52 Week high$1.55
52 Week low$0.49
52 Week low$0.49
Stock Snapshot
The current Context Therapeutics(CNTX) stock price is $1.13, with a market capitalization of 106.12M. The stock trades at a price-to-earnings (P/E) ratio of -4.11.
On 2025-12-19, Context Therapeutics(CNTX) stock traded between a low of $1.11 and a high of $1.28. Shares are currently priced at $1.13, which is +1.8% above the low and -11.7% below the high.
The Context Therapeutics(CNTX)'s current trading volume is 2.39M, compared to an average daily volume of 813.25K.
In the last year, Context Therapeutics(CNTX) shares hit a 52-week high of $1.55 and a 52-week low of $0.49.
In the last year, Context Therapeutics(CNTX) shares hit a 52-week high of $1.55 and a 52-week low of $0.49.
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CNTX. This list is generated using Robinhood data, and it’s not a recommendation.